Chugai Pharmaceutical Co (TSE:4519) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 1956. Start your Free Trial

What is Chugai Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Chugai Pharmaceutical Co's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Chugai Pharmaceutical Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Chugai Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

TSE:4519' s Cash-to-Debt Range Over the Past 10 Years
Min: 318.67 Med: 5579.98 Max: No Debt
Current: No Debt

During the past 13 years, Chugai Pharmaceutical Co's highest Cash to Debt Ratio was No Debt. The lowest was 318.67. And the median was 5579.98.

TSE:4519's Cash-to-Debt is ranked better than
99.71% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs TSE:4519: No Debt

Chugai Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Chugai Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Chugai Pharmaceutical Co Cash-to-Debt Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Chugai Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Chugai Pharmaceutical Co's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Cash-to-Debt falls into.

Chugai Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Chugai Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Chugai Pharmaceutical Co had no debt ⁽¹⁾.

Chugai Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Chugai Pharmaceutical Co had no debt ⁽¹⁾.

Chugai Pharmaceutical Co (TSE:4519) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Chugai Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (TSE:4519) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CHGCY:USA CHGCF:USA CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (TSE:4519) Headlines

No Headlines

Chugai Pharmaceutical Co (TSE:4519) Cash-to-Debt : No Debt (1) (As of Dec. 2023)